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Objectives. We examined the relations of elevated creatine
kinase (CK) and its myocardial band isoenzyme (CK-MB) to
clinical outcomes after percutaneous coronary intervention (PCI)
in patients enrolled in Integrilin (eptifibatide) to Minimize Plate-
let Aggregation and Coronary Thrombosis-II (trial) (IMPACT-
II), a trial of the platelet glycoprotein IIb/IIIa inhibitor eptifi-
batide.
Background. Elevation of cardiac enzymes often occurs after
PCI, but its clinical implications are uncertain.
Methods. Patients undergoing elective, scheduled PCI for any
indication were analyzed. Parallel analyses investigated CK (n 5
3,535) and CK-MB (n 5 2,341) levels after PCI (within 4 to 20 h).
Clinical outcomes at 30 days and 6 months were stratified by
postprocedure CK and CK-MB (multiple of the site’s upper
normal limit).
Results. Overall, 1,779 patients (76%) had no CK-MB eleva-
tion; CK-MB levels were elevated to 1 to 3 times the upper normal
limit in 323 patients (13.8%), to 3 to 5 times normal in 84 (3.6%),
to 5 to 10 times normal in 86 (3.7%), and to >10 times normal in
69 patients (2.9%). Elevated CK-MB was associated with an
increased risk of death, reinfarction, or emergency revasculariza-
tion at 30 days, and of death, reinfarction, or surgical revascular-
ization at 6 months. Elevated total CK to above three times
normal was less frequent, but its prognostic significance paral-
leled that seen for CK-MB. The degree of risk correlated with the
rise in CK or CK-MB, even for patients with successful proce-
dures not complicated by abrupt closure.
Conclusions. Elevations in cardiac enzymes, including small
increases (between one and three times normal) often not consid-
ered an infarction, are associated with an increased risk for
short-term adverse clinical outcomes after successful or unsuc-
cessful PCI.
(J Am Coll Cardiol 1999;33:88–96)
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Although an association between non–Q-wave myocardial
infarction (MI) and an increased risk of cardiac events has
been established for spontaneously occurring enzyme eleva-
tions (1–5), the clinical significance of abnormal elevation of
cardiac enzymes after percutaneous coronary intervention
(PCI) has been controversial. Comprehensive understanding
of the significance of periprocedural MIs is critical, because
they may occur in as many as 20% of patients (1,6,7) and are
often noted in asymptomatic patients and after uncomplicated
procedures (1). Early data from small numbers of low-risk
patients with limited long-term follow-up suggested that ele-
vations of cardiac enzymes after an intervention were incon-
sequential (1). More recent findings, however, indicate that
enzymatically defined postprocedure MIs carry an increased
risk of adverse clinical outcomes during extended follow-up
(2,3,8,9).
We hypothesized that postprocedural elevations of creatine
kinase (myocardial band isoenzyme) (CK-MB) also are asso-
ciated with adverse clinical outcomes at 30 days and at 6
months. To address this hypothesis and to delineate further the
prognostic importance of these postprocedural enzyme eleva-
tions, we evaluated this relationship in patients enrolled in the
Integrilin (eptifibatide) to Minimize Platelet Aggregation and
Coronary Thrombosis-II (IMPACT-II) study, a trial of a new
antiplatelet agent for reduction of ischemic complications of
PCI (10). The 4,010 patients who enrolled in this trial repre-
sented the largest available multicenter database to include a
cross section of patients undergoing elective, urgent, or emer-
gency PCI.
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Methods
IMPACT-II protocol. From November 30, 1993, to No-
vember 9, 1994, the IMPACT-II trial enrolled 4,010 patients at
82 centers in the United States. Details of the study have been
published (10). Patients were eligible if they were scheduled
for elective, urgent, or emergency PCI with a Food and Drug
Administration-approved device (balloon angioplasty, direc-
tional atherectomy, high-speed rotational atherectomy, or ex-
cimer laser ablation). Stent implantation was discouraged
except to manage abrupt closure. The protocol excluded
patients with coexisting conditions that could increase the risk
of bleeding with the glycoprotein IIb/IIa inhibitor eptifibatide
(Integrilin, COR Therapeutics, South San Francisco, Califor-
nia). The protocol was approved by the Institutional Review
Board at each center, and patients gave informed consent
before randomization.
Patients were randomly assigned to one of three treat-
ments: 1) eptifibatide 135/0.5, 135 mg/kg bolus followed by 0.5
mg/kg/min infusion for 20 to 24 h; 2) eptifibatide 135/0.75,
135 mg/kg bolus followed by 0.75 mg/kg/min infusion for 20 to
24 h; or 3) placebo bolus plus placebo infusion. Aspirin 325 mg
was given before the intervention and was to be continued
indefinitely. Heparin was given according to an algorithm to
maintain an activated clotting time (ACT) between 300 and
350 s throughout the procedure. The PCI was to be performed
immediately after the study drug bolus was given and the target
ACT had been obtained.
Blood samples for CK and CK-MB were obtained at
enrollment and at 6, 12 and 24 h after the initial bolus of study
drug. Additional samples were obtained if the patient devel-
oped signs or symptoms of ischemia. Enzymes were measured
according to local hospital standards.
Study design and definitions. Patients were excluded from
our analyses if they were scheduled to undergo direct or rescue
PCI for an acute MI (n 5 130), did not have a procedure (n 5
151), lacked an enzyme measure in the 4 to 20 h after PCI
(patients missing total CK, n 5 187; patients with total CK who
lacked an MB fraction, n 5 1,359), or were missing procedure
or event times or laboratory normals (CK, n 5 7; CK-MB, n 5
29) pertinent to these analyses. Clinical characteristics of the
patients with incomplete data did not differ substantively from
those of the remaining population (Table 1).
Measurement of cardiac enzymes was specified by the trial
protocol, which should have minimized the chance that en-
zymes (including MB fraction) may have been documented
preferentially in patients at higher risk for cardiac events. In
some cases, death or emergency bypass surgery shortly after
Abbreviations and Acronyms
CK-MB 5 creatine kinase (myocardial band isoenzyme)
IMPACT-II 5 Integrilin (eptifibatide) to Minimize Platelet Aggregation
and Coronary Thrombosis-II (trial)
MI 5 myocardial infarction
PCI 5 percutaneous coronary intervention
Table 1. Baseline Characteristics of Patients Included in and Excluded From Analysis
Variable
Included in Analysis Excluded From Analysis
CK
(n 5 3,535)
CK-MB
(n 5 2,341)
CK
(n 5 345)
CK-MB
(n 5 1,539)
Both
(n 5 157)
Age (yr) 61 (52, 69) 60 (52, 78) 62 (54, 69) 61 (53, 69) 62 (54, 71)
Weight (kg) 84 (74, 95) 84 (75, 95) 83 (73, 93) 83 (73, 95) 84 (76, 93)
Male sex 2,637 (75) 1,755 (75) 250 (73) 1,132 (74) 113 (72)
Hypertension 1,934 (55) 1,289 (55) 183 (53) 828 (54) 83 (53)
Diabetes 805 (23) 542 (23) 77 (22) 340 (22) 32 (20)
History of smoking 2,295 (65) 1,551 (67) 222 (65) 966 (63) 101 (65)
Hyperlipidemia 1,934 (55) 1,306 (56) 179 (52) 807 (54) 81 (52)
Cerebrovascular disease 63 (2) 47 (2) 12 (4) 28 (2) 9 (6)
Previous infarction 1,437 (41) 984 (42) 150 (44) 603 (39) 65 (41)
Previous bypass surgery 577 (16) 415 (18) 57 (17) 219 (14) 25 (16)
Peripheral vascular disease 214 (6) 147 (6) 34 (10) 101 (7) 18 (12)
Status at enrollment*
Unstable angina 1,262 (36) 845 (36) 141 (41) 558 (36) 71 (45)
Other (elective) 2,273 (64) 1,496 (64) 204 (59) 981 (64) 86 (55)
Reason for revascularization
Asymptomatic/positive functional study 284 (8) 173 (7) 37 (11) 148 (10) 16 (10)
Pain only with MI 317 (9) 224 (10) 24 (7) 117 (8) 7 (5)
Stable angina 550 (16) 352 (15) 54 (16) 252 (16) 25 (16)
Unstable angina 2,383 (67) 1,591 (68) 230 (67) 1,022 (66) 109 (69)
Systolic blood pressure (mm Hg) 130 (116, 145) 130 (116, 146) 130 (116, 146) 130 (117, 145) 130 (115, 146)
Diastolic blood pressure (mm Hg) 72 (65, 80) 72 (65, 80) 72 (65, 80) 72 (64, 80) 70 (62, 80)
Heart rate (beats/min) 68 (60, 78) 68 (60, 79) 68 (61, 79) 68 (60, 77) 68 (61, 80)
*Patients enrolled with acute MI are excluded from these analyses. Data presented are median (25th, 75th percentiles) or number (%) of patients.
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enrollment precluded completion of enzyme data. This is
reflected in the high rates of death and emergency bypass in
patients excluded from all analyses, including CK (Table 2).
Measurement of CK-MB, particularly in patients with normal
total CK, was determined by local laboratory protocol. Thus,
30-day and 6-month event rates in patients with complete
CK-MB data (those analyzed) were similar to those of the
overall population.
The 30-day composite endpoint for this analysis included
death from any cause, or a new MI, or urgent or emergency
repeat percutaneous or surgical intervention that occurred
$24 h after the index intervention. Urgent or emergency
bypass or repeat PCI was defined as an unanticipated proce-
dure performed to manage abrupt closure or suspected or
manifest ischemia. The MIs were classified by either enzyme or
electrocardiographic (ECG) criteria. The 6-month composite
end point for this analysis included death from any cause, MI,
and all percutaneous or surgical interventions (regardless of
urgency) occurring $24 h after the index PCI. As with the
30-day analyses, events associated with the index intervention
were excluded.
During the index hospitalization, MI was defined as eleva-
tion of CK-MB (or CK if CK-MB was unavailable) to at least
three times the upper limit of normal for the site, or new Q
waves $0.04 s in two or more anatomically contiguous leads. A
postdischarge MI was classified by elevation of CK-MB (or CK
if CK-MB was not available) to at least twice the site’s upper
limit of normal or new Q waves as described above. Procedure-
related MI was timed as occurring at the point of first device
activation.
All MIs occurring after enrollment were timed according to
the following hierarchy: 1) time of onset of symptoms or new
ECG changes if documented; 2) if no documentation of
ischemia, time of PCI if within 24 h before an abnormal
enzyme level or new Q waves; 3) if no documentation of
ischemia and no procedures within 24 h, time of first abnormal
enzyme or ECG with new Q waves. Importantly, cases in which
the onset of signs and symptoms of infarction occurred before
the end of the index procedure, and MIs within 24 h of the
index PCI that were ascribed to this procedure, were excluded
from composite and component end points.
An independent Clinical Events Committee blinded to
treatment assignment adjudicated all 30-day and 6-month
events. Length of hospital stay was defined as the difference (in
days) between the date of discharge and the date of the index
procedure.
Data management and statistical analysis. Demographic
and clinical data were collected on standard case report forms
and were verified against the medical record before being sent
to the Coordinating Center (Duke Clinical Research Institute)
for data entry. A follow-up visit $27 days after enrollment was
performed to assess the primary end point, and a telephone
interview was conducted at 6 months to evaluate long-term
outcomes. Medical records were reviewed for deaths, readmis-
sions, and angiograms reported by the patient at the 6-month
interview. Missing or inconsistent data were investigated.
We stratified patients by peak CK and CK-MB within 4 to
20 h after the index PCI (normal, peak CK or CK-MB 1 to 3
times normal, peak 3 to 5 times normal, peak 5 to 10 times
normal, and peak .10 times normal). For specific analyses,
patients were also stratified according to procedural complica-
tions, ultimate success, and device used. Procedural success
was defined as residual stenosis ,50% without a major clinical
event (thrombus, side-branch occlusion, or distal emboliza-
tion) as reported by the investigator.
Binary outcome variables are reported as frequencies and
percentages. Events during the 30-day and 6-month follow-up
periods are also depicted with Kaplan-Meier techniques (11).
We used multiple logistic regression analysis to construct a
model for the relationship between periprocedural elevations
of CK-MB, known baseline predictors of the 30-day end point
(weight, unstable angina, baseline platelet count, baseline
heart rate, previous bypass) (12), and treatment regimen with
the outcome of death, later MI, or later urgent or emergency
revascularization within 30 days of randomization, and death
or later MI within 6 months. The variables were analyzed to
assess the assumption that the log-odds of death or MI
Table 2. Clinical Outcomes
Outcome*
Included in Analysis Excluded From Analysis
CK
(n 5 3,535)
CK-MB
(n 5 2,341)
CK
(n 5 345)
CK-MB
(n 5 1,539)
Both
(n 5 157)
30-Day composite 179 (5.1) 139 (6.0) 43 (12.5) 83 (5.4) 25 (15.9)
Death 23 (0.7) 16 (0.7) 8 (2.3) 15 (1.0) 1 (0.6)
Myocardial infarction 87 (2.5) 74 (3.2) 7 (2.0) 20 (1.3) 3 (1.9)
Urgent bypass surgery 47 (1.3) 42 (1.8) 36 (10.4) 41 (2.7) 22 (14.0)
Urgent intervention 95 (2.7) 64 (2.7) 6 (1.7) 37 (2.4) 5 (3.2)
6-Month composite 928 (26.3) 647 (27.7) 139 (40.3) 420 (27.3) 45 (28.7)
Death 63 (1.8) 44 (1.9) 8 (2.3) 27 (1.8) 1 (0.6)
Myocardial infarction 187 (5.3) 137 (5.9) 15 (4.4) 65 (4.2) 6 (3.8)
Any bypass surgery 277 (7.8) 200 (8.5) 104 (30.1) 192 (11.8) 31 (19.7)
Any percutaneous intervention 657 (18.6) 441 (18.8) 38 (11.0) 254 (16.5) 18 (11.5)
*Patients enrolled with acute MI are excluded from these analyses. Data presented are number (%) of patients.
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independently related to the magnitude of postintervention
CK-MB elevation.
Results
Postprocedural CK and CK-MB. Table 3 shows the strat-
ification of patients according to peak CK and CK-MB fraction
after the index PCI. The incidence and magnitude of observed
elevations were higher for patients with unstable rather than
stable angina (p 5 0.001 for CK-MB; p 5 0.004 for total CK).
Patients scheduled for an elective PCI were included in
these analyses regardless of the indication or baseline CK or
CK-MB values. In most cases, a baseline CK value was
available (93%; 3,285/3,535) and was normal (89.0%; 2,925
patients). Of patients with available data, elevated CK before
the index PCI was reported in 13.6% of patients with unstable
angina (165/1,214) and in 9.4% of other patients (195/2,071).
Baseline elevations of CK-MB were noted in 13.5% of patients
with available data, in 19.5% of patients with unstable angina
(118/604), and in 10.2% of other patients (11/1,091). Patients
with baseline CK or CK-MB elevations were more likely to
have postprocedural elevations and to have larger elevations.
Prognostic significance of postintervention elevated CK
and CK-MB. Figures 1 and 2 show the point estimates and
95% confidence intervals for the 30-day composite and com-
ponent event rates by total CK and CK-MB stratum. Of
patients with minimally elevated CK-MB (one to three times
normal), 9.0% experienced reinfarction (after the index PCI),
death, or urgent or emergency revascularization by 30 days,
about three times the composite event rate of patients with
normal postprocedural CK-MB (2.9%; p , 0.0001) (complete
data may be obtained from Dr. Tardiff). A proportionate
relation between magnitude of the CK-MB and the composite
30-day event rate was noted for elevations up to five times the
upper limit of normal. The incidence of later adverse outcomes
was high, but not consistently proportional to the magnitude of
the peak CK-MB, in patients with elevations .5 times normal.
A similar relation between elevated postprocedure level and
later adverse outcomes was seen for total CK.
Patients with postprocedural enzyme elevations were also
more likely to have late cardiac events within 6 months (Figs.
3 and 4). Of patients who had modest (one to three times
normal) postprocedural elevations, 8.7% had a new MI within
6 months, over twice the rate of MI in patients with normal
postprocedural CK-MB. Again, findings were similar for total
CK. Although a strong proportionate relation between eleva-
tion of CK-MB after the index PCI and 6-month event rates
was seen for death and MI, a less consistent trend was
Figure 1. Point estimates and 95% confidence intervals for frequency
of later clinical events at 30 days, by postintervention CK stratum
(from left to right): 0–1 times normal, 1–3 times normal, 3–5 times
normal, 5–10 times normal, or .10 times normal. MI 5 myocardial
infarction; CABG 5 coronary artery bypass graft; PTCA 5 percuta-
neous transluminal coronary angioplasty.
Figure 2. Point estimates and 95% confidence intervals for frequency
of later clinical events at 30 days, by postintervention CK-MB stratum
(from left to right): 0–1 times normal, 1–3 times normal, 3–5 times
normal, 5–10 times normal, or .10 times normal. Abbreviations as in
Figure 1.
Table 3. Postprocedure Peak CK and CK-MB by Diagnostic Category
Postprocedure Peak
All Patients Unstable Angina Elective
CK
(n 5 3,535)
CK-MB
(n 5 2,341)
CK
(n 5 1,262)
CK-MB
(n 5 845)
CK
(n 5 2,273)
CK-MB
(n 5 1,496)
Normal 3,111 (88.0) 1,779 (76.0) 1,084 (85.9) 609 (72.1) 2,027 (89.2) 1,170 (78.2)
1–3 times normal 327 (9.3) 323 (13.8) 135 (10.7) 139 (16.5) 192 (8.5) 184 (12.3)
3–5 times normal 58 (1.6) 84 (3.6) 29 (2.3) 32 (3.8) 29 (1.3) 52 (3.5)
5–10 times normal 24 (0.7) 86 (3.7) 8 (0.6) 30 (3.6) 16 (0.7) 56 (3.7)
.10 times normal 15 (0.4) 69 (2.9) 6 (0.5) 35 (4.1) 9 (0.4) 34 (2.3)
Data presented are number (%) of patients.
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observed for bypass, and no apparent relationship was noted
for repeat interventions. All revascularizations, regardless of
urgency, were included in the 6-month composite end point.
Timing of postprocedural events. Figures 5 and 6 show the
Kaplan-Meier curves for the incidence of death and later MI to
30 days and 6 months as a function of postprocedural CK-MB.
Although a large proportion of events occurred within the first
several days after the index intervention, the curves separated
even more after this initial period, most notably for patients
with small elevations (one to three times normal).
Relationship between procedural events and prognostic
significance. Of 562 patients with elevated postprocedural
CK-MB, 441 of 557 patients (79.2%) with complete procedural
data met criteria for PCI success and had no abrupt closure.
Acute symptomatic events consistent with abrupt closure were
evident in 53 (9.5%) of the patients whose CK-MB became
elevated, and another 63 patients (11.3%) did not achieve
procedural success (Table 4). Procedures complicated by
abrupt closure were associated with highest risk for later
events. Not surprisingly, procedural success was associated
with lower event rates, whether abrupt closure occurred or not.
Table 5 shows the relationship between CK-MB elevations
and later clinical outcomes at 30 days and 6 months in patients
with uncomplicated, successful procedures. Again, a propor-
tionate relation between the postprocedural enzyme level and
clinical outcomes was shown for the composite and component
endpoints at 30 days and 6 months. Patients with the smallest
postprocedure elevations (one to three times normal), which
did not meet the definition of a periprocedural MI, were more
than twice as likely as patients with normal postprocedural
enzymes to have had a later MI at 30 days (3.6% vs. 1.5%). The
Figure 3. Point estimates and 95% confidence intervals for frequency
of later clinical events at 6 months, by postintervention CK stratum
(from left to right): 0–1 times normal, 1–3 times normal, 3–5 times
normal, 5–10 times normal, or .10 times normal. Abbreviations as in
Figure 1.
Figure 4. Point estimates and 95% confidence intervals for frequency
of later clinical events at 6 months, by postintervention CK-MB
stratum (from left to right): 0–1 times normal, 1–3 times normal, 3–5
times normal, 5–10 times normal, or .10 times normal. Abbreviations
as in Figure 1.
Figure 5. Kaplan-Meier curves illustrating the incidence of occurrence
of death and later infarction at 30 days in patients with postprocedural
CK-MB elevation 0–1 times normal (heavy solid line), 1–3 times
normal (light solid line), 3–5 times normal (heavy short dashes), 5–10
times normal (light short dashes), or .10 times normal (long dashes).
Figure 6. Kaplan-Meier curves illustrating the incidence of occurrence
of death and later infarction at 6 months in patients with postproce-
dural CK-MB elevation 0–1 times normal (heavy solid line), 1–3 times
normal (light solid line), 3–5 times normal (heavy short dashes), 5–10
times normal (light short dashes), or .10 times normal (long dashes).
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relation between outcome and postprocedural CK-MB at 6
months was prominent for death and MI, less consistent for
bypass surgery, and not apparent for angioplasty, as was
observed in the larger population.
Relation between device type and prognostic significance.
Angioplasty was the predominant technique used in the
IMPACT-II study. Use of a directional or high-speed rota-
tional atherectomy device in conjunction with angioplasty was
associated with a greater incidence of postprocedural increases
in CK-MB than was angioplasty (p , 0.0001; Table 6). Because
intracoronary stent use was discouraged during the index PCI
except as a bailout device, the number of stented patients was
small. For all devices, including stents, a relation between
enzyme elevations and the 30-day and 6-month composite
event rates was observed (Table 7).
Relationship between elevated cardiac enzymes and length
of hospital stay. Elevated cardiac enzymes above three times
normal after PCI were associated with a longer initial hospital
stay. A proportionate relation between postprocedure CK or
CK-MB and time from procedure to discharge was seen. The
Table 4. Procedural Success and Abrupt Closure and Clinical Outcome
Composite Death Infarction Bypass* Angioplasty*
CK-MB normal (n 5 1,779)
30 days 51 (2.9) 6 (0.3) 26 (1.5) 12 (0.7) 29 (1.6)
6 months 443 (24.9) 27 (1.5) 70 (3.9) 123 (6.9) 329 (18.5)
CK-MB abnormal, successful,†
no abrupt closure (n 5 441)
30 days 49 (11.3) 5 (1.1) 27 (6.2) 11 (2.5) 26 (5.9)
6 months 151 (34.6) 10 (2.3) 45 (10.4) 48 (10.9) 93 (21.1)
CK-MB abnormal, successful,
abrupt closure (n 5 27)
30 days 8 (32.0) 0 (0) 7 (28.0) 1 (3.7) 4 (14.8)
6 months 12 (46.2) 0 (0) 7 (28.0) 5 (18.5) 7 (25.9)
CK-MB abnormal, unsuccessful,
no abrupt closure (n 5 63)
30 days 13 (21.7) 1 (1.6) 6 (10.2) 7 (11.1) 2 (3.2)
6 months 22 (36.7) 2 (3.2) 7 (11.9) 12 (19.1) 7 (11.1)
CK-MB abnormal, unsuccessful,
abrupt closure (n 5 26)
30-days 15 (60.0) 4 (15.4) 7 (29.2) 8 (30.8) 3 (11.5)
6 months 16 (61.5) 4 (15.4) 7 (29.2) 9 (34.6) 5 (19.2)
*30-Day bypass and angioplasty include urgent/emergency procedures only; 6-month bypass and angioplasty include
all procedures. †Success 5 residual stenosis ,50% and no thrombus, side-branch occlusion, or distal embolization. For
no elevation vs. elevation with success, p , 0.0001 (infarction, the composite end point), p 5 0.006 (bypass surgery). For
no elevation vs. elevation without success, p 5 0.0001 (infarction, bypass, and the composite end point); p 5 0.002
(death). Data presented are number (%) of patients.
Table 5. Clinical Outcomes in Patients With Successful Procedures Without Abrupt Closure
CK-MB Composite Death Infarction Bypass* Angioplasty*
Normal (n 5 1,634)
30 days 43 (2.6) 5 (0.3) 25 (1.5) 8 (0.5) 24 (1.5)
6 months 400 (24.5) 25 (1.5) 66 (4.0) 105 (6.4) 298 (18.2)
1–3 times normal (n 5 281)
30 days 22 (7.9) 1 (0.4) 10 (3.6) 5 (1.8) 12 (4.3)
6 months 91 (32.4) 4 (1.4) 23 (8.2) 24 (8.5) 60 (21.4)
3–5 times normal (n 5 68)
30 days 9 (13.9) 1 (1.5) 5 (7.7) 2 (2.9) 3 (4.4)
6 months 25 (37.9) 2 (2.9) 7 (10.8) 8 (11.8) 14 (20.6)
5–10 times normal (n 5 51)
30 days 11 (21.6) 1 (2.0) 6 (12.0) 2 (3.9) 7 (13.7)
6 months 18 (35.3) 1 (2.0) 7 (14.0) 5 (9.8) 11 (21.6)
.10 times normal (n 5 41)
30 days 7 (18.0) 2 (4.9) 6 (15.4) 2 (4.9) 4 (9.8)
6 months 17 (43.6) 3 (7.3) 8 (20.5) 11 (26.8) 8 (19.5)
Success denotes residual stenosis ,50% and no thrombus, side-branch occlusion, or distal embolization; abrupt
closure, abrupt closure during index procedure. *30-Day bypass and angioplasty include urgent and emergency
procedures only; 6-month bypass and angioplasty include all revascularizations. Data presented are number (%) of
patients.
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CK elevations were associated with prolongation of the time
from procedure to discharge from a median of 2 days (range,
0 to 31 days; interquartile range, 1 to 2 days) for patients with
normal postprocedure CK to 5 days (1 to 26 days, 3 to 6 days) for
patients with a postprocedure peak CK from three to five times
normal. Patients with markedly elevated CK (.10 times normal)
had the longest hospital stays with a median time from procedure
to discharge of 7 days (1 to 46 days, 4 to 11 days). A subtler but
similar relationship was evident for CK-MB. There was a gradual
rise in the upper quartile limit for CK-MB elevations up to five
times normal. The median stay increased from 2 days (0 to 37
days, 1 to 2 days) for patients with no elevation to 3 days (1 to 14
days, 2 to 6 days) for patients with increases from 5 to 10 times
normal, and to 4 days (1 to 46 days, 3 to 7 days) for patients with
postprocedure CK-MB .10 times normal.
Predictive modeling. The magnitude of the peak CK-MB
after the index PCI had a highly significant, nonlinear
relationship to the composite 30-day (death or MI) and
6-month (death, MI, or revascularization) end points. The
effect was nearly linear for CK-MB elevations of up to six
times normal, then reached a plateau at higher levels (for
30-day composite with spline, x2 5 147.66, p , 0.0001; for
6-month composite with spline, x2 5 42.41, p , 0.0001; for
6-month death or infarction with spline, x2 5 72.66, p ,
0.0001; Fig. 7).
After adjustment for known baseline predictors of the
30-day end point (weight, unstable angina, baseline platelet
count, baseline heart rate, previous bypass surgery) (12),
postprocedure CK-MB remained significantly associated with
30-day (x2 5 135.09, p , 0.0001) and 6-month outcomes (x2 5
32.56, p , 0.0001). This persisted for the 30-day composite
outcome after further adjustment for age and the presence of
diabetes (x2 5 139.74, p , 0.0001).
Eptifibatide treatment had no significant relationship
with the clinical effects of postintervention enzyme eleva-
tions. We found only a trend toward an interaction (x2 5
2.75; p 5 0.097) between eptifibatide 135/0.75 treatment and
degree of enzyme elevation for the 30-day composite out-
come, such that the risk of adverse outcomes by 30 days in
patients with elevations was somewhat lower for patients in
the eptifibatide 135/0.75 arm than for those in the other
treatment arms. This trend remained after adjustment for age and
diabetes (x2 5 3.027, p 5 0.082).
Discussion
In this study, patients who had an elevated CK-MB level
after coronary procedures were at increased risk for death, MI,
and urgent revascularization at 30 days, and for death, MI, and
surgical revascularization at 6 months. The degree of risk was
proportional to the magnitude of the rise in CK-MB. We ob-
served no threshold for a substantial increase in postprocedural
events in any category of serum CK and CK-MB elevation,
although there was little added risk associated with levels of
CK-MB greater than six times normal. Importantly, even patients
with minimal (one to three times normal) increases in CK-MB—
elevations usually not recognized as cardiac events in the context
of clinical trials—were at increased risk for later adverse out-
comes. After controlling for clinical factors such as weight,
acuteness of presentation, baseline heart rate, and previous
Table 6. Postprocedure CK-MB by Device Type
CK-MB
Angioplasty
(n 5 1616)
Atherectomy*
(n 5 369)
Rotablator*
(n 5 292)
Stent
(n 5 102)
Normal 1,331 (82) 214 (58) 193 (66) 55 (54)
1–3 times normal 176 (11) 85 (23) 55 (19) 19 (19)
3–5 times normal 36 (2.2) 30 (8) 17 (6) 6 (6)
5–10 times normal 37 (2.3) 26 (7) 13 (4) 16 (16)
.10 times normal 36 (2.2) 14 (4) 14 (5) 6 (6)
*Includes use in combination with other devices. Data presented are number (%) of patients.
Table 7. Clinical Outcomes by CK-MB Level and
Device Type
CK-MB 30-Day Composite 6-Month Composite
Normal
Angioplasty only 41 (3.1) 337 (25.3)
Atherectomy 3 (1.4) 54 (25.2)
Rotablator 4 (2.1) 39 (20.2)
Stent 4 (7.3) 15 (27.3)
1–3 times normal
Angioplasty only 19 (10.9) 52 (29.6)
Atherectomy 5 (5.9) 29 (34.1)
Rotablator 4 (7.3) 22 (40.0)
Stent 3 (15.8) 7 (36.8)
3–5 times normal
Angioplasty only 7 (20.6) 16 (44.4)
Atherectomy 3 (10.3) 7 (24.1)
Rotablator 3 (18.8) 9 (56.3)
Stent 1 (16.7) 2 (33.3)
5–10 times normal
Angioplasty only 10 (28.6) 15 (41.7)
Atherectomy 6 (26.1) 8 (34.8)
Rotablator 3 (25.0) 5 (41.7)
Stent 2 (28.6) 6 (42.9)
.10 times normal
Angioplasty only 8 (22.9) 18 (50.0)
Atherectomy 1 (8.3) 4 (28.6)
Rotablator 4 (40.0) 7 (58.3)
Stent 4 (66.7) 5 (83.3)
Data presented are number (%) of patients.
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bypass surgery, we found that an increased CK-MB remained an
important predictor of adverse outcomes.
Not surprisingly, the gradient of risk was defined by the
success of the procedure, whether abrupt closure occurred, and
by the magnitude of the postprocedural elevation. However,
even among patients with successful PCI (no residual stenosis
.50%, and no thrombus, side-branch occlusion, distal embo-
lization, or abrupt closure), those with postprocedural eleva-
tions were at higher risk for new cardiac events within 6
months than were those without an abnormal increase in
postprocedural CK-MB.
Postprocedure MI has been reported to carry an increased
risk for cardiac mortality during extended follow-up (8,13).
These data extend previous findings in that only modest
enzymatic elevations (not usually classified as MI in this
setting) are associated with increased risk, and that peri-
interventional MI is associated with short-term as well as
long-term adverse outcomes.
Study limitations. The interpretation of these data may be
complicated by several possible limitations. Patients referred
for enrollment in IMPACT-II could represent a high-risk
subgroup. This is unlikely, as prospective risk stratification
indicated that the largest proportion of patients (97%) were
referred for elective coronary interventions (10). The inci-
dence of periprocedural elevations of CK-MB is similar to that
reported in other interventional studies (2,3).
Because CK-MB is more specific for myocardial damage
than total CK, and because increases in total CK may not
always correlate with increases in CK-MB (13), patients who
did not have an MB fraction measured were excluded from
some analyses. The IMPACT-II protocol called for enzyme
sampling at designated times, but CK-MB may have been
measured preferentially in patients with elevated CK or at high
risk of cardiac events. To address this limitation, parallel
analyses were performed of total CK instead of CK-MB.
Results of these analyses compared well with those limited to
patients with CK-MB, indicating that the sample used in this
analysis appeared to represent the overall study population.
Overall event rates at 30 days and 6 months for patients from
whom no enzymes were obtained suggest that they were similar
in terms of cardiac risk to those for whom complete enzyme
data were available (Table 2). Exclusion of the high-risk
patients who experienced early death or bypass surgery (which
precluded capture of postprocedure enzyme data) strengthens
rather than limits the results.
A drawback to multicenter trials is the variation among
investigative sites. Different methods to determine enzyme
levels, and varying standards of normal, can confound assess-
ment of abnormal CK-MB levels. Reported CK-MB values
were divided by meticulously verified institutional normals, to
translate them into a measure that was reasonably consistent
from site to site. The use of these myocardial enzyme ratios
should permit generalizable comparisons.
Implications. Although several studies have shown the
relation between postprocedural enzyme elevations and long-
term outcomes (13), this is the first report suggesting that the
survival curves of CK-MB-positive and -normal patient groups
may separate within the first year.
The prognostic relationship observed for periprocedural
elevations is similar to that seen with spontaneously occurring
non–Q-wave MIs. This implies that abnormal elevation of
cardiac enzymes, whether associated with PCI and regardless
of magnitude, should be interpreted as an MI. Although it
remains to be seen whether strategies that improve outcomes
after spontaneous MI are also effective for periprocedural MI,
it follows that close clinical management is indicated for these
patients. Perhaps more important, therapeutic strategies that
aim to reduce the incidence and severity of peri-intervention
MI are clearly warranted. Antiplatelet agents, particularly the
glycoprotein IIb/IIIa inhibitors, have been shown to reduce the
incidence of recurrent acute coronary events and should be
strongly considered for routine use (10,14).
It has been unclear whether procedures using newer inter-
ventional devices are equally predictive of periprocedural
infarction. The use of directional or high-speed rotational
atherectomy was associated with more frequent and greater
increases in CK-MB after intervention in IMPACT-II, con-
firming previous reports (3). Measured increases in CK-MB
were associated with increased 30-day and 6-month composite
event rates, regardless of device. Although we did not adjust
for differences in lesion characteristics, these findings suggest
that increases in CK-MB observed with these newer devices
carry prognostic significance. Prospective evaluation of devices
should include long-term follow-up as well as an assessment of
the incidence of periprocedural MI, to document their effects
on morbidity and mortality.
The interpretation of periprocedural enzyme elevations is
particularly complex for patients with evolving MIs and ele-
vated enzymes at the time of PCI. These data suggest that such
patients are more likely to have elevated enzymes after the
procedure. Later risk could relate to a preintervention MI or a
procedural event. However, adjustment for a diagnosis of
Figure 7. Probability of the 6-month composite of death and infarction
as a function of CK-MB elevation. ULN 5 upper limit of normal.
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unstable angina at presentation did not abolish the prognostic
significance of elevated CK-MB after intervention.
The relation between postintervention microinfarctions and
later adverse outcomes has not been fully settled. It is not clear
whether myocardial necrosis or the severity of the patient’s
underlying illness is responsible for the associated risk. Several
investigators have failed to show that the prognostic import of
elevated enzymes is explained by more severe underlying
disease (4,9). Although baseline factors known to predict the
30-day end point were used in the predictive modeling, these
analyses may not have included complete consideration of impor-
tant coronary morphology or procedural characteristics. Further
study of these variables and extended patient follow-up are
needed to clarify this relationship and provide insight into the
mechanism of enzyme elevations after coronary intervention.
In any case, the consistency of these data—the strong
dose-response relationship between the magnitude of the
postprocedural CK and CK-MB elevation and 30-day and
6-month outcomes, and the results of multivariable model-
ing—strongly argue against these observations being a result of
chance. These data clearly justify the classification of a CK-MB
elevation above three times normal as an MI within the context
of a clinical trial and suggest consideration of lesser elevations.
Although postprocedural enzyme elevations should be inter-
preted with consideration of lesion morphology and the clinical
setting, these findings solidly support systematic assessment of
CK-MB or other cardiac markers after all coronary interven-
tions. Patients who have a CK-MB elevation greater than three
times normal may benefit from close observation in an inpa-
tient setting after the procedure and from medical therapies
appropriate for an uncomplicated non–Q-wave MI. A more
limited period of observation appears safe for patients with
small (one to three times normal), transient CK-MB eleva-
tions. Even in these cases, however, there should be a height-
ened awareness of the increased risk for later events and
careful outpatient monitoring.
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